BTK inhibitor Calquence: Significant lyzing to relieve cytokine storm in patients infected with the new coronavirus COVID-19

AstraZeneca has announced the results of its new clinical study, showing that its Bruton tyrosine kinase (BTK) inhibitor Calquinib can reduce the inflammatory response of the new coronavirusCOVID-19infectionpatients and improve the patient's prognosisCalence was evaluated in 19 patients with COVID-19infection sourcingpatients who suffered from severe respiratory diseases due to COVID-19 virus infectionresults showed that all but one patient had an increasing amount of oxygen demand at the start of treatment, and all but four patients received high-flow oxygen or invasive mechanical ventilationThe oxygen demand in most patients after Calence was administered significantly improved and the inflammatory indicators tended to normalize, half of the patients who needed mechanical ventilation were able to pull the tube after calencethe company noted that inflammatory cytokine storms are the main cause of respiratory disease in these patients, and evidence suggests that BTK-mediated pulmonary macrophage signaling disorders play an important role in cytokine storms and pneumonia in patients with COVID-19 infection"This encouraging preliminary data provides important information for the launch of Phase II clinical trials worldwide, and we look forward to further deepening our understanding of the potential treatment of patients with severe COVID-19 infections in these trials," said Jos?Baselga, Executive Vice President of Oncology Research and Development at AZ"